NCT01356485 - Safety Study of MP4CO in Adult Sickle Cell Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Anemia, Sickle CellSickle Cell AnemiaSickle Cell DiseaseSickle Cell DisordersHemoglobin SC DiseaseSickle Cell Hemoglobin C Disease

Interventions

DRUG

MP4CO

43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution

DRUG

Sodium chloride solution

Normal saline (0.9% sodium chloride solution)

Trial Locations (5)

Hôpital Henri Mondor, Créteil

Sickle Cell Unit, University of West Indies, Kingston

Rafic Hariri University Hospital, Beirut

Guy's Hospital, London

King's College London, London